Updating the PGMY Primers and Probes for Improved Detection of HPV68a: Validation of Version 2 of the PGMY-CHUV Assay

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2014 Aug 22

PMID 25143570

Citations 8

Authors

C Estrade

R Sahli

Affiliations

Soon will be listed here.

Abstract

HPV68a is not efficiently detected by PCR with the PGMY primers. Version 2 of the PGMY-CHUV assay (PGv2) was developed from version 1 (PGv1) to evaluate HPV68-discordant results with the Anyplex II HPV28 assay. We now report that PGv2 is significantly more sensitive than PGv1 for HPV68a and as sensitive and specific for the other HPV genotypes during a 1-year prospective validation (n = 714 samples).

Citing Articles

Clinical Performance of Cobas 6800 for the Detection of High-Risk Human Papillomavirus in Urine Samples.

Hajjar B, Raheel U, Manina R, Simpson J, Irfan M, Waheed Y Vaccines (Basel). 2023; 11(6).

PMID: 37376460 PMC: 10305403. DOI: 10.3390/vaccines11061071.

Comparison between the Roche Cobas 4800 Human Papillomavirus (HPV), Abbott RealTime High-Risk HPV, Seegene Anyplex II HPV28, and Novel Seegene Allplex HPV28 Assays for High-Risk HPV Detection and Genotyping in Mocked Self-Samples.

Bell M, Verberckmoes B, Devolder J, Vermandere H, Degomme O, Guimaraes Y Microbiol Spectr. 2023; 11(4):e0008123.

PMID: 37284753 PMC: 10433804. DOI: 10.1128/spectrum.00081-23.

Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections.

Basiletti J, Valls J, Poklepovich T, Fellner M, Rol M, Alonso R PLoS One. 2022; 17(11):e0278117.

PMID: 36417453 PMC: 9683586. DOI: 10.1371/journal.pone.0278117.

Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.

Correa R, Baena A, Valls J, Colucci M, Mendoza L, Rol M PLoS One. 2022; 17(7):e0272205.

PMID: 35905130 PMC: 9337688. DOI: 10.1371/journal.pone.0272205.

NanoString Technology for Human Papillomavirus Typing.

Rajeevan M, Patel S, Li T, Unger E Viruses. 2021; 13(2).

PMID: 33513748 PMC: 7911781. DOI: 10.3390/v13020188.

References

Estrade C, Sahli R . Comparison of Seegene Anyplex II HPV28 with the PGMY-CHUV assay for human papillomavirus genotyping. J Clin Microbiol. 2014; 52(2):607-12. PMC: 3911335. DOI: 10.1128/JCM.02749-13. View

Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F . A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10(4):321-2. DOI: 10.1016/s1470-2045(09)70096-8. View

Van de Velde N, Boily M, Drolet M, Franco E, Mayrand M, Kliewer E . Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012; 104(22):1712-23. DOI: 10.1093/jnci/djs395. View

Steinau M, Swan D, Unger E . Type-specific reproducibility of the Roche linear array HPV genotyping test. J Clin Virol. 2008; 42(4):412-4. DOI: 10.1016/j.jcv.2008.03.004. View

Eklund C, Zhou T, Dillner J . Global proficiency study of human papillomavirus genotyping. J Clin Microbiol. 2010; 48(11):4147-55. PMC: 3020877. DOI: 10.1128/JCM.00918-10. View

Munoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L . Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006; 24 Suppl 3:S3/1-10. DOI: 10.1016/j.vaccine.2006.05.115. View

Clifford G, Franceschi S, Diaz M, Munoz N, Villa L . Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24 Suppl 3:S3/26-34. DOI: 10.1016/j.vaccine.2006.05.026. View

Estrade C, Menoud P, Nardelli-Haefliger D, Sahli R . Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol. 2011; 49(10):3474-81. PMC: 3187290. DOI: 10.1128/JCM.05039-11. View

Smith J, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R . Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121(3):621-32. DOI: 10.1002/ijc.22527. View

10.

Gravitt P, Peyton C, Apple R, Wheeler C . Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998; 36(10):3020-7. PMC: 105104. DOI: 10.1128/JCM.36.10.3020-3027.1998. View

11.

Zur Hausen H . Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009; 384(2):260-5. DOI: 10.1016/j.virol.2008.11.046. View

12.

Gravitt P, Peyton C, Alessi T, Wheeler C, Coutlee F, Hildesheim A . Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000; 38(1):357-61. PMC: 88724. DOI: 10.1128/JCM.38.1.357-361.2000. View